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The pathogenesis of venous malformation needs to be clariﬁed and, although various treatment mo-
dalities are available, an optimal treatment has not been established. A 19-year-old girl presented with
venous malformation of the rectosigmoid colon. She showed severe anemia due to rectal hemorrhage;
her hemoglobin (Hb) level was 4.9 g/dl. A large venous malformation connected to an internal hemor-
rhoid was evident by endoscopy. Neither surgical resection nor sclerotherapy was indicated because of
high blood ﬂow in the venous malformation. Octreotide was initiated. However, the bleeding continued
and she required persistent blood transfusions. We started propranolol in the 5th week of hospitaliza-
tion. Celecoxib, which was started for her knee pain was found to be predictably effective, and we
administered it regularly. Propranolol and celecoxib were gradually increased, the rectal bleeding
decreased, and her anemia improved. Five months after the initiation of propranolol and celecoxib, she
could maintain Hb at 15 g/dl without transfusion. Propranolol can contract blood vessels and celecoxib
can inhibit vascular endothelial growth factor (VEGF) to result in anti-angiogenesis. This combination
therapy might be useful for controlling intractable venous malformation.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Venous malformations are the most common kind of vascular
malformations and are a result of errors in vascular morphogenesis
[1]. Bleeding is the most common symptom of gastrointestinal (GI)
vascular malformation [2]. Various treatment modalities are avail-
able, including endoscopy to destroy vascular malformations by
sclerotherapy with ethanol, therapeutic angiography with super-
selective embolization, especially for acute hemorrhage, and
surgery [1]. When these interventions are not possible, are con-
traindicated or have been ineffective, as often happens in patients
with multiple lesions distributed across several segments of the
digestive tract or when the lesion is widespread, or when the
patient has comorbidities that prevent the use of invasive pro-
cedures, pharmacological treatment is the only possible alternative
[3,4]. We report here a case of rectosigmoid colon venous mal-
formation that was successfully treated with propranolol and
celecoxib.þ81 99 265 7196.
c.jp (Y. Okamoto).
Inc. This is an open access article u1. Case report
A 19-year-old female was hospitalized due to melena and severe
anemia. Her Hb level was 4.9 g/dl. No one else in her family had
similar problems.
She hadhadhemorrhoids since shewas3 years old.When shewas
5 years old, she was referred to our hospital with a pale complexion.
Her Hb was 4.2 g/dl. A perirectal vascular lesion was found by
computed tomography (CT) and magnetic resonance imaging (MRI).
Laparoscopic resection of the pelvic lesion was performed, and the
diagnosis was perirectal venous malformation. A residual lesion was
found by postoperative MRI. When she was 13 years old, bleeding
increased again, and hemorrhoidectomy and resection of the venous
malformation were performed. After the operation, the bleeding
improved andwas only seen in the case of constipation. However, the
bleeding got worse again when she was 19 years old.
The patient did not have thrombocytopenia or a clotting disor-
der. A thickened rectal wall (Fig. 1) and phleboliths around the
rectum that suggested widespread venous malformation were
observed by enhanced CT examination (Fig. 2). Dilated veinsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Enhanced CT. A contrast-enhanced CT scan showed a thickened rectal wall.
Fig. 3. Colonoscopy. Colonoscopy showed several dilated veins.
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(Fig. 3). Neither surgical resection nor sclerotherapy was indicated
because the lesion showed high blood ﬂow and occupied a broad
area around her rectum. Surgical resection would also require
colostomy.
On day 17 of admission, Octreotide was initiated at 40 mcg/day
and then increased to 54 mcg/day. However, bleeding continued
and there was no decrease in the quantity of red blood cell (RBC)
transfusions, which were required every 3 days. Twenty-two units
of RBC were transfused in the ﬁrst month of admission. She was
referred to our department for further treatment. In the 5th week of
hospitalization, we started propranolol at 0.5 mg/kg/day. Although
the Hb level increased to 9e10 mg/dl after the initiation of pro-
pranolol, bleeding continued. Celecoxib, which was started to treat
her knee pain, was found to be predictably effective, and therefore
was administered regularly. Propranolol and celecoxib were grad-
ually increased to 2.7 mg/kg/day and 9.0 mg/kg/day, respectively.
The rectal bleeding gradually decreased and anemia improved. She
received 18 and 8 units of RBC in the 2nd and 3rd months ofFig. 2. 3D CT. A contrast-enhanced 3D CT scan showed perirectal phleboliths.admission, respectively. Once she was discharged, her anemia got
worse again and she required an additional 6 units of RBC in the 4th
month, probably due to increased daily activity. Five months after
the initiation of propranolol and celecoxib, she could maintain Hb
at 15 g/dl without transfusion, although d-dimer has been high as
7.4e13.4 mg/ml (<1.0) which indicate a consumption.2. Discussion
In cases inwhich endoscopy, therapeutic angiography or surgery
is not indicated, pharmacological treatment is the only alternative
therapy for GI vascular malformation. Estrogen-progesterone,
thalidomide and octreotide have been used as prophylaxis for
hemorrhage due to GI vascular malformation [5].
Estrogen-progesterone has been used to control obscure GI
bleeding in patients with vascular malformation. The mechanisms
of action are vascular stability, improved coagulation, decreased
mesenteric blood ﬂow. But they have not been found to be uni-
formly successful and are controversial. Equally important is that
hormones are associated with some signiﬁcant side effects [5].
High concentrations of VEGF are associated with aberrant
angiogenesis and the formation of vascular malformations with a
thinner muscle layer, which causes high vascular fragility and a
tendency to hemorrhage [6,7].
Thalidomide can inhibit VEGF, which is the rationale for its use
to treat vascular malformation. A randomized trial that compared
treatment with thalidomide with iron supplementation in 55 pa-
tients showed a signiﬁcant reduction in bleeding episodes. The
response rate in the thalidomide-treated group was 71.4%
compared to only 3.7% in the control group. That trial also
demonstrated a signiﬁcant decrease in serum levels of VEGF in the
treatment group [7]. However, thalidomide must not be used in
women with child-bearing potential because of teratogenesis.
Therefore, thalidomide was not an option for our patient. Octreo-
tide is another drug that can inhibit angiogenesis, constrict
splanchnic vessels, increase vascular resistance and increase
platelet aggregation [8]. A meta-analysis of 3 prospective studies
with a total of 62 patients showed a 76% response rate [8]. There-
fore, we used this drug as the ﬁrst-line therapy. Unfortunately, our
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department to seek alternative treatments.
Propranolol has become a valuable drug for the treatment of
hemangiomas. Propranolol also has effects such as vasoconstriction,
blocking of angiogenesis through its effects on VEGF, and induction
of apoptosis [9]. A recent randomized study demonstrated that 88%
of infantile hemangioma patients who received a propranolol
regimen showed improvement byweek 5 [10]. There is evidence that
propranolol is effective in the treatment of lymphatic malformations
that fall into vascular malformation [11]. Our patient did not show a
clear response, probably due to widespread vascular malformation.
However, she did show a response with the addition of cele-
coxib. It has been demonstrated that celecoxib can inhibit angio-
genesis due to the inhibition of VEGF expression in an animal model
[12]. There has been no previous report that celecoxib is effective
for the treatment of vascular malformation in a clinical setting.
The combination of propranolol and celecoxib might be useful
for controlling massive bleeding from large intractable vascular
malformation without adverse events. The synergistic mechanisms
of propranolol and celecoxib should be clariﬁed.
3. Conclusions
Sclerotherapy, therapeutic angiography, surgery and traditional
pharmacological treatment were not available in this case. The
combination of propranolol and celecoxib was effective for control-
ling bleeding from venous malformation without adverse events.
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